QIAGEN

QIAGEN NV is a provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The firm automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D, and industrial applications, primarily forensics). The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

QIAGEN surpasses 2022 targets, eyes growth in diagnostics and biopharma

QIAGEN's strong performance in 2022 exceeded expectations, supported by robust financials and strategic acquisitions.
Despite market challenges, the company remains confident in achieving its 2023 targets, focusing on growth opportunities in diagnostics and biopharma.
Emphasis on innovation, customer knowledge, and strategic shifts position QIAGEN well for sustained growth and leadership in the industry.

QIAGEN surpasses Q1 sales targets, eyes China growth opportunities

QIAGEN's Q1 2023 performance exceeded expectations, with strong sales growth and margin improvements.
The company remains focused on driving growth through product innovation and strategic market expansion.
Challenges include cautious customer spending and evolving market dynamics, particularly in China.
Opportunities lie in capitalizing on strong product performance, investing in new solutions, and expanding market reach.

QIAGEN reports strong Q2 earnings, eyes China growth opportunities

QIAGEN's Q2 performance was solid, driven by key growth areas, but challenges persist with net sales decline and market volatility. The company's strengths in base business sales and focus on growth pillars position it well for future opportunities in China and market expansion.

QIAGEN surpasses Q3 expectations, focuses on sustained growth strategies

QIAGEN's Q3 2023 performance exceeded expectations, showcasing strong financials and strategic leadership changes, with a reaffirmed full-year outlook for 2023.
The company's strengths lie in successful product pillars, sustained growth strategies, and a strategic focus on non-COVID products in key markets.
Challenges include debt repayment impacts, external market uncertainties, and competitive differentiation in expanding product offerings, while opportunities exist in market expansion, innovation, and automation investments.

QIAGEN surpasses Q4 expectations, eyes strategic growth opportunities

QIAGEN's Q4 performance exceeded expectations, showcasing strong growth and profitability.
Challenges include potential risks in Q1 and delays impacting certain product growth.
Strategic investments and upcoming launches present opportunities for continued growth and market expansion.
Overall, QIAGEN's focus on innovation and strategic acquisitions positions them for sustained success in the future.

QIAGEN beats Q1 sales targets, eyes FDA approvals for growth

QIAGEN's Q1 2024 performance exceeded expectations, with strong sales in Diagnostic Solutions. The company reaffirmed its full-year outlook and highlighted advancements in its product portfolio. Despite challenges in the Chinese market, QIAGEN remains focused on growth opportunities and efficient capital allocation.

QIAGEN surpasses Q3 expectations, boosts outlook amid leadership change

QIAGEN delivered strong Q3 results, surpassing expectations and demonstrating improved profitability. Despite leadership changes, the company's strategic initiatives and global positioning bode well for future growth and resilience in the face of market dynamics.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

QIAGEN (QGEN) registered revenue growth across majority of its geographies and each of its operating segments in Q4

QIAGEN (QGEN) Q4 Earnings Beat Estimates, Margins Expand

Exact Sciences

One just wrapped up a multi-billion-dollar acquisition while the other elected to remain independent.

Better Buy: Exact Sciences vs. Qiagen

Investors can retain QIAGEN (QGEN) stock for now, thanks to its solid prospects.

Here's Why You Should Hold on to QIAGEN (QGEN) Stock Now

Virgin Galactic

A pair of companies involved in cutting-edge, 21st century businesses both took it on the chin.

2 Stocks That Tumbled on Thursday

Why Qiagen Stock Crashed 24% Today

Qiagen NV QGEN, +0.78% shares plummeted more than 25% in late trading on Tuesday after the company announced that a strategic review had ended with a decision to not break up nor sell the business.

Qiagen stock plunges more than 25% after opting against sale

Osmotica Pharmaceuticals Plc

OSMT vs. QGEN: Which Stock Is the Better Value Option?

OSMT vs. QGEN: Which Stock Should Value Investors Buy Now?

Here’s Why Qiagen Skyrocketed Over 43% in November

QIAGEN (QGEN) and DiaSorin begin the commercial launch of the QFT-Plus test in the United States, following the FDA clearance.

QIAGEN and DiaSorin Get FDA Approval for LIAISON QFT-Plus

Thermo Fisher Scientific

Shares of the Dutch diagnostic test manufacturer Qiagen popped after it confirmed ongoing buyout discussions with Thermo Fisher Scientific and others.

Will Thermo Fisher Buy Qiagen?

QIAGEN (QGEN) announces the expansion of partnership with LabCorp (LH) to make genetic information available for clinical and research purposes.

QIAGEN Expands Existing Deal With LabCorp for Better Treatment

OSMT or QGEN: Which Is the Better Value Stock Right Now?

QIAGEN (QGEN) pins hopes on its key strategic collaborations with Hamilton Robotics and Tecan for the pre-analytical handling of blood tubes.

QIAGEN Rides on Solid QuantiFERON-TB Sales Amid Several Woes

Dutch genetic-testing company Qiagen confirmed late Friday it's fielding several offers from potential suitors interested in acquiring it. Qiagen stock rose 8.8% on Friday.

Medtech Stock With 28% Gain This Week Confirms It's Fielding Buyout Bids

New management at Qiagen NV (NYSE: QGEN) would likely pursue several opportunities for portfolio rationalization and cost reduction, according to JPMorgan.

JPMorgan Upgrades Qiagen After Product Surveys, Valuation Analysis

Qiagen stock popped in bullish volume Thursday on a report medical technology giant Thermo Fisher Scientific could buy it for $8 billion. It would be one of Thermo Fisher's biggest buys.

This Medtech Stock Jumped Bullishly On A Rumored $8 Billion Takeover

Shares of Qiagen N.V. QGEN, +9.89% surged 3.3% in premarket trading Thursday, after J.P.

Qiagen's stock extends surge after J.P. Morgan swings to bullish from bearish

QIAGEN (QGEN) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

QIAGEN (QGEN) Catches Eye: Stock Jumps 9.9%

QIAGEN N.V. (QGEN) CEO Thierry Bernard on Q3 2019 Results - Earnings Call Transcript

We are impressed with QIAGEN's (QGEN) year-over-year growth across majority of operating segments in Q3.

QIAGEN (QGEN) Beats Q3 Earnings Estimates, Cuts Revenue View

Qiagen (QGEN) delivered earnings and revenue surprises of 2.86% and -0.26%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Qiagen (QGEN) Tops Q3 Earnings Estimates

Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Qiagen (QGEN) Q3 Earnings Preview: What's in the Cards?

The launch of the kits is expected to bolster QIAGEN's (QGEN) Life Sciences Business Area

QIAGEN (QGEN) Launches QIAseq FastSelect Technology Kits

If the dismal preliminary sales performance was not enough, then the news pertaining to QIAGEN's (QGEN) current CEO Peer M. Schatz's stepping down came as another huge blow.

QIAGEN Down on Dim Q3 Prelim Sales, Startling CEO Departure

Illumina

QIAGEN (QGEN) aims to fast-track the adoption of NGS-based IVD test and improve patient outcomes through the new partnership deal.

News for QIAGEN Stock (QGEN)